Arcagy/ Gineco Group

This study tests whether a combination of two drugs (dostarlimab and niraparib) works better than standard chemotherapy for a rare, fast-growing cancer called carcinosarcoma of the uterus or ovary. About 138 women whose cancer has spread or returned after at least one round of ch…

This study is for people with advanced ovarian cancer that did not respond well to initial chemotherapy. It tests whether a more frequent, weekly chemotherapy schedule can help shrink tumors enough for successful surgery and improve survival. About 250 participants will be random…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can improve outcomes for a rare and aggressive ovarian cancer that mainly affects young women. About 27 participants will receive the combination treatment followed by surgery. The goal …

This study is for women with advanced ovarian cancer who have had complete surgery and chemotherapy. It compares two maintenance treatments: niraparib alone versus niraparib plus bevacizumab. The goal is to see which approach better delays cancer return. About 390 participants wi…